Home / Health / FDA Clears Wegovy, Zepbound: No Suicidal Thoughts Link
FDA Clears Wegovy, Zepbound: No Suicidal Thoughts Link
13 Jan
Summary
- FDA removes warnings about suicidal thoughts for GLP-1 drugs.
- Wegovy, Zepbound, and Saxenda are among affected medications.
- Review covered over 107,000 patients in 91 clinical trials.
The U.S. health regulator has directed drugmakers to remove warnings about potential suicidal thoughts from widely used GLP-1 weight-loss drugs. This guidance impacts medications such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, as well as Novo's Saxenda.
The U.S. Food and Drug Administration's request stems from a comprehensive review of clinical trial data. This analysis, involving 91 trials with over 107,000 participants, found no evidence linking GLP-1 receptor agonists to an increased risk of suicidal thoughts or behavior.
Originally developed for type 2 diabetes, GLP-1 drugs mimic a gut hormone to suppress appetite. The FDA's latest conclusion reinforces an earlier preliminary review, asserting that these drugs do not pose a greater psychiatric risk compared to placebos.
